Rina Davis, MD
Interventional Pain Medicine · North Syracuse, NYNPI 1770578494
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. MDD US Operations, LLC accounts for 65.1% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $6,291 and has fallen 96.2% since, to $242 in 2025.
Across 159 payments — averaging $54.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$6K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$392
- Pfizer$258
- Collegium Pharmaceutical, Inc.$223
- Medtronic$171
- plus $921 from 20 others
What the payments were for
- Consulting fees$2633%
- Speaking & faculty fees$4,00046%
- Travel & lodging$96211%
- Food & beverage$3,32039%
- Education$751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 18 | $5,615 |
| AbbVie(2 entities) | 37 | $1,041 |
| Teva Pharmaceuticals USA, Inc. | 12 | $392 |
| Pfizer | 17 | $258 |
| Collegium Pharmaceutical, Inc. | 17 | $223 |
| Medtronic | 3 | $171 |
| Arbor Pharmaceuticals, Inc. | 14 | $134 |
| Amgen | 7 | $128 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $105 |
| Biohaven Pharmaceuticals, Inc. | 2 | $88 |
| Lundbeck LLC | 3 | $78 |
| International Rehabilitative Sciences, Inc | 2 | $56 |
| Scilex Pharmaceuticals Inc. | 3 | $48 |
| Vertex | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| IBSA Pharma Inc. | 2 | $32 |
| Nevro Corp. | 1 | $26 |
| Fidia Pharma USA Inc. | 2 | $25 |
| Tersera Therapeutics LLC | 2 | $23 |
| Daiichi Sankyo Inc. | 1 | $20 |
| AstraZeneca | 1 | $14 |
| Novartis | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| SPR Therapeutics, Inc | 3 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Si-bone, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYOBLOC$4,709
- BOTOX$389
- AJOVY$214
- INTELLIS ADAPTIVESTIM$105
How this compares
$8,620 in reported general payments places this provider in the 70th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 12 | $106 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in North Syracuse
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Hemant KaliaRochester$179K
- Martin FerrilloAlbany$164K
- George ChaseKew Gardens$102K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
- Gerard DegregorisNew York$49K
- Jafar SiddiquiWilliamsville$45K
- Alexander WeingartenSyosset$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.